首页 > 最新文献

Alzheimer's & Dementia最新文献

英文 中文
Frequent at-home multimodal measurements are more sensitive to progression than the gold-standard clinic-based ADAS-Cog composite scale 频繁的在家多模态测量比基于临床的金标准ADAS - Cog复合量表对进展更敏感
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_104932
Laura M Rueda-Delgado, Florentine M Barbey, Alison R Buick, Shannon Diggin, John Dyer, Hugh Nolan, James B Rowe, Brian Murphy
<div> <section> <h3> Background</h3> <p>The detection of progression is key to the statistical power of placebo-controlled clinical trials. This is a challenge in dementia, as disease progression is confounded with natural aging, and as widely used assessments (CDR, ADAS-Cog) lack sensitivity and are administered only infrequently and in specialist settings.</p> <p>We report a non-interventional study conducted with 10 pharma companies to evaluate the feasibility and value of capturing repeated multimodal digital assessments with Alzheimer's dementia patients, using the NeuLogiq<sup>TM</sup> platform in the home over 12 months. The difference in progression between mild dementia and matched controls serves as a model of placebo vs. an efficacious intervention. We quantify the statistical power of NeuLogiq digital measures, relative to conventional endpoints.</p> </section> <section> <h3> Method</h3> <p>Seven UK sites recruited Alzheimer's type mild dementia patients (<i>n</i> = 59, ACE-III scores >60 and ≤88) and controls (<i>n</i> = 60). Participants were asked to perform 8 cognitive tasks presented on a tablet with synchronous low-burden EEG, autonomously at home. Overnight EEG was also recorded. NeuLogiq sessions were staggered throughout the year, with 26 samples requested per task. Benchmark paper-based assessments (including ADAS-Cog) were administered in-clinic (months 0, 6, 12) and blood plasma was collected (months 6, 12). Progression was analyzed with mixed effects models, for benchmarks and a predefined selection of Cumulus variables.</p> </section> <section> <h3> Result</h3> <p>Over 52 weeks, there was a real but modest difference in progression on ADAS-Cog (beta=2.03, <i>p</i> = 0.021) and DSST (beta=-5.67, <i>p</i> = 0.006), and no significant difference on VPA, with all showing familiarization effects (Figure 1). Of the 41 predefined NeuLogiq measures, several exhibited a similar/larger effect size to ADAS-Cog (Figure 2). Two survived correction for multiple comparisons: tablet-based associative memory task (beta=-4.52, <i>p</i> <0.001) and psychomotor task (beta= 42.4, <i>p</i> <0.001). Post-hoc analysis showed that <i>p</i>-tau positive/negative patients were separated on the memory task, and on the symbol coding executive function task (Figure 3).</p> </section> <section> <h3> Conclusion</h3> <p>Individual tablet-based tasks, completed autonomously at home by mild dementia patients, are more sensitive measurements of disease progression than ADAS-Cog. In on-going analysis we are quantifying
背景:病情进展的检测是安慰剂对照临床试验统计效力的关键。这在痴呆症中是一个挑战,因为疾病进展与自然衰老相混淆,并且广泛使用的评估(CDR, ADAS - Cog)缺乏敏感性,并且只在专业环境中很少使用。我们报告了一项与10家制药公司进行的非介入研究,以评估在家中使用NeuLogiq TM平台对阿尔茨海默氏痴呆症患者进行重复多模式数字评估的可行性和价值。轻度痴呆和匹配对照组之间的进展差异可以作为安慰剂与有效干预的模型。相对于传统终点,我们量化了NeuLogiq数字测量的统计能力。方法在英国7个研究中心招募阿尔茨海默氏型轻度痴呆患者(n = 59, ACE‐III评分为>;60和≤88)和对照组(n = 60)。参与者被要求在家中自主完成8项在平板电脑上呈现的认知任务,该平板电脑具有同步低负荷脑电图。同时记录夜间脑电图。NeuLogiq的测试在一年中是错开的,每个任务需要26个样本。在临床(第0、6、12个月)进行基于基准论文的评估(包括ADAS - Cog),并收集血浆(第6、12个月)。用混合效应模型分析进度,作为基准和预先选择的积云变量。在52周内,ADAS‐Cog (β =2.03, p = 0.021)和DSST (β =‐5.67,p = 0.006)的进展存在真实但适度的差异,VPA无显著差异,均显示熟悉效应(图1)。在41个预定义的NeuLogiq测量中,有几个显示出与ADAS‐Cog相似或更大的效应量(图2)。两项多重比较校正后存活:基于平板电脑的联想记忆任务(beta=‐4.52,p <0.001)和精神运动任务(beta= 42.4, p <0.001)。事后分析显示,p - tau阳性/阴性患者在记忆任务和符号编码执行功能任务上是分开的(图3)。结论:与ADAS‐Cog相比,轻度痴呆患者在家中自主完成的个体片剂任务对疾病进展更为敏感。在正在进行的分析中,我们正在量化多模式/多变量/复合测量可能提供的额外统计力量,以及由此导致的痴呆临床试验规模、持续时间和风险的潜在减少。
{"title":"Frequent at-home multimodal measurements are more sensitive to progression than the gold-standard clinic-based ADAS-Cog composite scale","authors":"Laura M Rueda-Delgado,&nbsp;Florentine M Barbey,&nbsp;Alison R Buick,&nbsp;Shannon Diggin,&nbsp;John Dyer,&nbsp;Hugh Nolan,&nbsp;James B Rowe,&nbsp;Brian Murphy","doi":"10.1002/alz70856_104932","DOIUrl":"10.1002/alz70856_104932","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The detection of progression is key to the statistical power of placebo-controlled clinical trials. This is a challenge in dementia, as disease progression is confounded with natural aging, and as widely used assessments (CDR, ADAS-Cog) lack sensitivity and are administered only infrequently and in specialist settings.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;We report a non-interventional study conducted with 10 pharma companies to evaluate the feasibility and value of capturing repeated multimodal digital assessments with Alzheimer's dementia patients, using the NeuLogiq&lt;sup&gt;TM&lt;/sup&gt; platform in the home over 12 months. The difference in progression between mild dementia and matched controls serves as a model of placebo vs. an efficacious intervention. We quantify the statistical power of NeuLogiq digital measures, relative to conventional endpoints.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Seven UK sites recruited Alzheimer's type mild dementia patients (&lt;i&gt;n&lt;/i&gt; = 59, ACE-III scores &gt;60 and ≤88) and controls (&lt;i&gt;n&lt;/i&gt; = 60). Participants were asked to perform 8 cognitive tasks presented on a tablet with synchronous low-burden EEG, autonomously at home. Overnight EEG was also recorded. NeuLogiq sessions were staggered throughout the year, with 26 samples requested per task. Benchmark paper-based assessments (including ADAS-Cog) were administered in-clinic (months 0, 6, 12) and blood plasma was collected (months 6, 12). Progression was analyzed with mixed effects models, for benchmarks and a predefined selection of Cumulus variables.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Result&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Over 52 weeks, there was a real but modest difference in progression on ADAS-Cog (beta=2.03, &lt;i&gt;p&lt;/i&gt; = 0.021) and DSST (beta=-5.67, &lt;i&gt;p&lt;/i&gt; = 0.006), and no significant difference on VPA, with all showing familiarization effects (Figure 1). Of the 41 predefined NeuLogiq measures, several exhibited a similar/larger effect size to ADAS-Cog (Figure 2). Two survived correction for multiple comparisons: tablet-based associative memory task (beta=-4.52, &lt;i&gt;p&lt;/i&gt; &lt;0.001) and psychomotor task (beta= 42.4, &lt;i&gt;p&lt;/i&gt; &lt;0.001). Post-hoc analysis showed that &lt;i&gt;p&lt;/i&gt;-tau positive/negative patients were separated on the memory task, and on the symbol coding executive function task (Figure 3).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Individual tablet-based tasks, completed autonomously at home by mild dementia patients, are more sensitive measurements of disease progression than ADAS-Cog. In on-going analysis we are quantifying ","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_104932","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of plasma biomarkers for Alzheimer's disease with cognitive change among Hispanic/Latino adults: preliminary findings from HCHS/SOL and SOL-INCA 阿尔茨海默病血浆生物标志物与西班牙/拉丁裔成年人认知变化的关联:HCHS/SOL和SOL‐INCA的初步发现
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_105946
Freddie Márquez, Wassim Tarraf, Natasha Z. Anita, Deisha F Valencia, Fernando Daniel Testai, Humberto Parada Jr., Carmen R Isasi, Paola Filigrana, Martha L Daviglus, Haibo Zhou, Linda C Gallo, Charles Decarli, Douglas R. Galasko, Bharat Thyagarajan, Hector M Gonzalez
<div> <section> <h3> Background</h3> <p>The relationship between plasma biomarkers for Alzheimer's disease and longitudinal cognitive decline in diverse and underserved communities remains poorly understood. We investigated the associations between baseline plasma biomarkers and changes in cognitive performance over 13.5 years in a diverse cohort of Hispanic/Latino individuals.</p> </section> <section> <h3> Method</h3> <p>We used data from the Hispanic Community Health Study/Study of Latinos (Visit 1; 2008-2011) and the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA; Visit 2; 2016-2018) and SOL-INCA2 (Visit 3; 2022-2024) ancillary studies. We included 2,343 participants (aged 45-74 years at Visit 1; 54.4 years on average) that completed their third visit of cognitive testing and had plasma samples analyzed (Quanterix Simoa HD-X) for amyloid-beta (Aβ<sub>42/40</sub>), phosphorylated tau-181 (pTau-181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) at Visit 1. Global cognitive performance was a standardized average composite of four z-scored cognitive tests relative to the baseline mean and standard deviation. The plasma biomarker measures were dichotomized to focus on high-risk groups (bottom 10<sup>th</sup> percentile for Aβ<sub>42/40</sub>; top 10<sup>th</sup> percentile for pTau-181, pTau-181/Aβ<sub>42</sub>, NfL, and GFAP). Additionally, we used a risk-index score based on the count of plasma biomarker (excluding pTau-181/Aβ<sub>42</sub>) measures that are high-risk (0,1, and ≥2). We used multilevel linear models to examine cognitive aging trajectories with models covarying for sex, Hispanic/Latino background, and <i>APOE</i> e4 genotype.</p> </section> <section> <h3> Result</h3> <p>In each model, age was associated with decrements in global cognitive change (Table 1). Individuals in the top 10<sup>th</sup> percentile for pTau-181, pTau-181/Aβ<sub>42</sub>, NfL, and GFAP had more pronounced age-related declines in global cognitive performance (Figures 1 and 2). We observed no differences in age-related global cognitive change for individuals in the bottom 10<sup>th</sup> percentile for Aβ<sub>42/40</sub>. Individuals with higher risk (≥2 biomarkers in the high-risk groups) had more pronounced age-related cognitive decline.</p> </section> <section> <h3> Conclusion</h3> <p>Preliminary findings suggest plasma biomarkers for pTau-181, pTau-181/Aβ<sub>42</sub>, NfL, and GFAP predict cognitive decline before symptoms manifest. Individuals with high levels of these biomarkers are at elevated risk for age-
阿尔茨海默病血浆生物标志物与不同和服务不足社区纵向认知能力下降之间的关系仍然知之甚少。我们调查了基线血浆生物标志物与13.5年以上西班牙裔/拉丁裔个体认知能力变化之间的关系。方法:我们使用来自西班牙裔社区健康研究/拉丁裔研究(访问1;2008 - 2011)、拉丁裔研究-神经认知衰老调查(访问2;2016 - 2018)和SOL - INCA2(访问3;2022 - 2024)辅助研究的数据。我们纳入了2,343名参与者(第一次访问时年龄为45 - 74岁,平均54.4岁),他们完成了第三次认知测试,并在第一次访问时分析了血浆样本(Quanterix Simoa HD‐X)的淀粉样蛋白- β (Aβ 42/40)、磷酸化tau - 181 (pTau - 181)、神经丝轻链(NfL)和胶质纤维酸性蛋白(GFAP)。总体认知表现是相对于基线平均值和标准偏差的四项z得分认知测试的标准化平均复合。血浆生物标志物测量结果进行了二分类,重点关注高危组(Aβ 42/40最低10个百分位数;pTau - 181、pTau - 181/Aβ 42、NfL和GFAP最高10个百分位数)。此外,我们使用了基于血浆生物标志物(不包括pTau - 181/ a β 42)计数的高风险(0、1和≥2)风险指数评分。我们使用多层线性模型来检验认知衰老轨迹,这些模型与性别、西班牙/拉丁裔背景和APOE e4基因型共变。在每个模型中,年龄与整体认知变化的减少相关(表1)。pTau - 181、pTau - 181/Aβ 42、NfL和GFAP得分在前10百分位的个体在全球认知表现上的年龄相关性下降更为明显(图1和2)。我们观察到,在Aβ 42/40最低10个百分位数的个体中,与年龄相关的整体认知变化没有差异。高风险个体(≥2个生物标志物在高风险组)有更明显的与年龄相关的认知衰退。结论:初步发现提示pTau - 181、pTau - 181/Aβ 42、NfL和GFAP的血浆生物标志物可在症状出现前预测认知能力下降。这些生物标志物水平较高的个体发生与年龄相关的认知能力下降的风险较高。轨迹差异的阈值因生物标志物而异,轨迹差异在年龄较大时更为明显,表明可能存在非线性变化。
{"title":"Association of plasma biomarkers for Alzheimer's disease with cognitive change among Hispanic/Latino adults: preliminary findings from HCHS/SOL and SOL-INCA","authors":"Freddie Márquez,&nbsp;Wassim Tarraf,&nbsp;Natasha Z. Anita,&nbsp;Deisha F Valencia,&nbsp;Fernando Daniel Testai,&nbsp;Humberto Parada Jr.,&nbsp;Carmen R Isasi,&nbsp;Paola Filigrana,&nbsp;Martha L Daviglus,&nbsp;Haibo Zhou,&nbsp;Linda C Gallo,&nbsp;Charles Decarli,&nbsp;Douglas R. Galasko,&nbsp;Bharat Thyagarajan,&nbsp;Hector M Gonzalez","doi":"10.1002/alz70856_105946","DOIUrl":"10.1002/alz70856_105946","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The relationship between plasma biomarkers for Alzheimer's disease and longitudinal cognitive decline in diverse and underserved communities remains poorly understood. We investigated the associations between baseline plasma biomarkers and changes in cognitive performance over 13.5 years in a diverse cohort of Hispanic/Latino individuals.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We used data from the Hispanic Community Health Study/Study of Latinos (Visit 1; 2008-2011) and the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA; Visit 2; 2016-2018) and SOL-INCA2 (Visit 3; 2022-2024) ancillary studies. We included 2,343 participants (aged 45-74 years at Visit 1; 54.4 years on average) that completed their third visit of cognitive testing and had plasma samples analyzed (Quanterix Simoa HD-X) for amyloid-beta (Aβ&lt;sub&gt;42/40&lt;/sub&gt;), phosphorylated tau-181 (pTau-181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) at Visit 1. Global cognitive performance was a standardized average composite of four z-scored cognitive tests relative to the baseline mean and standard deviation. The plasma biomarker measures were dichotomized to focus on high-risk groups (bottom 10&lt;sup&gt;th&lt;/sup&gt; percentile for Aβ&lt;sub&gt;42/40&lt;/sub&gt;; top 10&lt;sup&gt;th&lt;/sup&gt; percentile for pTau-181, pTau-181/Aβ&lt;sub&gt;42&lt;/sub&gt;, NfL, and GFAP). Additionally, we used a risk-index score based on the count of plasma biomarker (excluding pTau-181/Aβ&lt;sub&gt;42&lt;/sub&gt;) measures that are high-risk (0,1, and ≥2). We used multilevel linear models to examine cognitive aging trajectories with models covarying for sex, Hispanic/Latino background, and &lt;i&gt;APOE&lt;/i&gt; e4 genotype.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Result&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In each model, age was associated with decrements in global cognitive change (Table 1). Individuals in the top 10&lt;sup&gt;th&lt;/sup&gt; percentile for pTau-181, pTau-181/Aβ&lt;sub&gt;42&lt;/sub&gt;, NfL, and GFAP had more pronounced age-related declines in global cognitive performance (Figures 1 and 2). We observed no differences in age-related global cognitive change for individuals in the bottom 10&lt;sup&gt;th&lt;/sup&gt; percentile for Aβ&lt;sub&gt;42/40&lt;/sub&gt;. Individuals with higher risk (≥2 biomarkers in the high-risk groups) had more pronounced age-related cognitive decline.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Preliminary findings suggest plasma biomarkers for pTau-181, pTau-181/Aβ&lt;sub&gt;42&lt;/sub&gt;, NfL, and GFAP predict cognitive decline before symptoms manifest. Individuals with high levels of these biomarkers are at elevated risk for age-","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_105946","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microstructural and Water Exchange Alterations in ARIA-E in a Real-World Cohort Receiving Anti-Amyloid Therapy 在接受抗淀粉样蛋白治疗的现实世界队列中,ARIA - E的微观结构和水交换改变
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_107657
Christopher A Brown, Manuel Taso, Sandhitsu R. Das, Danielle Hing, Emily McGrew, Paul A. Yushkevich, Dawn Mechanic-Hamilton, Ilya M. Nasrallah, David C Alsop, John A. Detre, David A. Wolk
<div> <section> <h3> Background</h3> <p>ARIA-E represents the greatest risk associated with anti-amyloid therapy (AAT) and is thought to be due to excessive inflammatory response resulting in FLAIR abnormalities on imaging and occasionally symptomatic manifestations. While FLAIR MRI monitoring for ARIA-E is now routinely performed, additional MRI contrast mechanisms could provide improved detection and mechanistic insights. We investigated perivascular spaces, microstructural alterations, and parenchymal water permeability in a real-world cohort receiving AAT using novel MRI techniques.</p> </section> <section> <h3> Methods</h3> <p>Eight participants receiving AAT at the University of Pennsylvania underwent advanced imaging paired with clinical safety MRIs at baseline and during treatment. Advanced imaging sequences included multi-shell diffusion MRI to assess microstructure, an ultralong TE T2-weighted sequence to evaluate perivascular spaces structures, and a novel T2-saturation based water-exchange sequence. These sequences add <15 minutes to the MRI protocol and can be performed on clinical 3T scanners. We measured microstructure in a composite ROI consisting of cortical regions typically associated with high amyloid deposition as well as in global white matter. Water exchange was calculated specifically in regions that developed ARIA.</p> </section> <section> <h3> Results</h3> <p>2 patients developed ARIA-E after 2 months of treatment that prompted suspension of treatment: (1) mild symptomatic case that went on to develop mild ARIA-H at 3 months with resolution of ARIA-E, (2) moderate case that progressed to severe ARIA-E at 3 months. At baseline these individuals had lower Neurite Density Index (NDI) and Orientation Dispersion Index (ODI) compared to no ARIA (ARIA-) patients (Figure 1). At 2 months, they had marked increases in NDI and ODI that resolved by 3 months (Figure 2A). In contrast, there was gradual increase in water exchange and white matter free water fraction (FWF) at 2 and 3 months compared to ARIA- (Figure 2B). ARIA-E and ARIA-H is also readily visualized on water exchange sensitive maps (Figure 3). Quantification of perivascular volume is ongoing.</p> </section> <section> <h3> Conclusion</h3> <p>Measures of water diffusion and exchange enhance our understanding of ARIA with findings consistent with transient increases in cellularity at ARIA onset and prolonged increases in parenchymal water permeability and edema. Early results suggest microstructure could predict risk for future ARIA. Additional data collection continues.</
背景:ARIA‐E是与抗淀粉样蛋白治疗(AAT)相关的最大风险,被认为是由于过度的炎症反应导致FLAIR成像异常和偶尔的症状表现。虽然FLAIR MRI监测ARIA‐E现在是常规的,但额外的MRI对比机制可以提供改进的检测和机制见解。我们使用新的MRI技术研究了现实世界中接受AAT的队列血管周围空间、微观结构改变和实质水渗透性。方法在宾夕法尼亚大学接受AAT治疗的8名参与者在基线和治疗期间接受了高级成像和临床安全性mri。先进的成像序列包括用于评估微观结构的多壳扩散MRI,用于评估血管周围空间结构的超沿TE T2加权序列,以及基于T2饱和度的新型水交换序列。这些序列增加了15分钟的MRI协议,可以在临床3T扫描仪上进行。我们测量了复合ROI的微观结构,包括通常与高淀粉样蛋白沉积相关的皮质区域以及全球白质。在发生ARIA的地区专门计算了水交换。结果2例患者在治疗2个月后出现ARIA‐E,导致暂停治疗:(1)轻度症状患者在3个月时发展为轻度ARIA‐E,但ARIA‐E消退;(2)中度症状患者在3个月时发展为严重ARIA‐E。在基线时,与没有ARIA (ARIA‐)的患者相比,这些个体的神经突密度指数(NDI)和定向弥散指数(ODI)较低(图1)。2个月时,患者的NDI和ODI明显增加,3个月后消失(图2A)。相反,与ARIA‐相比,在2和3个月时,水交换和白质游离水分数(FWF)逐渐增加(图2B)。ARIA‐E和ARIA‐H也很容易在水交换敏感图上可视化(图3)。血管周围体积的定量正在进行中。结论水的扩散和交换增强了我们对ARIA的认识,其结果与ARIA发病时细胞数量的短暂增加和实质水渗透性和水肿的延长一致。早期的研究结果表明,微观结构可以预测未来ARIA的风险。继续收集其他数据。
{"title":"Microstructural and Water Exchange Alterations in ARIA-E in a Real-World Cohort Receiving Anti-Amyloid Therapy","authors":"Christopher A Brown,&nbsp;Manuel Taso,&nbsp;Sandhitsu R. Das,&nbsp;Danielle Hing,&nbsp;Emily McGrew,&nbsp;Paul A. Yushkevich,&nbsp;Dawn Mechanic-Hamilton,&nbsp;Ilya M. Nasrallah,&nbsp;David C Alsop,&nbsp;John A. Detre,&nbsp;David A. Wolk","doi":"10.1002/alz70856_107657","DOIUrl":"10.1002/alz70856_107657","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;ARIA-E represents the greatest risk associated with anti-amyloid therapy (AAT) and is thought to be due to excessive inflammatory response resulting in FLAIR abnormalities on imaging and occasionally symptomatic manifestations. While FLAIR MRI monitoring for ARIA-E is now routinely performed, additional MRI contrast mechanisms could provide improved detection and mechanistic insights. We investigated perivascular spaces, microstructural alterations, and parenchymal water permeability in a real-world cohort receiving AAT using novel MRI techniques.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Eight participants receiving AAT at the University of Pennsylvania underwent advanced imaging paired with clinical safety MRIs at baseline and during treatment. Advanced imaging sequences included multi-shell diffusion MRI to assess microstructure, an ultralong TE T2-weighted sequence to evaluate perivascular spaces structures, and a novel T2-saturation based water-exchange sequence. These sequences add &lt;15 minutes to the MRI protocol and can be performed on clinical 3T scanners. We measured microstructure in a composite ROI consisting of cortical regions typically associated with high amyloid deposition as well as in global white matter. Water exchange was calculated specifically in regions that developed ARIA.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;2 patients developed ARIA-E after 2 months of treatment that prompted suspension of treatment: (1) mild symptomatic case that went on to develop mild ARIA-H at 3 months with resolution of ARIA-E, (2) moderate case that progressed to severe ARIA-E at 3 months. At baseline these individuals had lower Neurite Density Index (NDI) and Orientation Dispersion Index (ODI) compared to no ARIA (ARIA-) patients (Figure 1). At 2 months, they had marked increases in NDI and ODI that resolved by 3 months (Figure 2A). In contrast, there was gradual increase in water exchange and white matter free water fraction (FWF) at 2 and 3 months compared to ARIA- (Figure 2B). ARIA-E and ARIA-H is also readily visualized on water exchange sensitive maps (Figure 3). Quantification of perivascular volume is ongoing.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Measures of water diffusion and exchange enhance our understanding of ARIA with findings consistent with transient increases in cellularity at ARIA onset and prolonged increases in parenchymal water permeability and edema. Early results suggest microstructure could predict risk for future ARIA. Additional data collection continues.&lt;/","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_107657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visceral Adipose Tissue Shows Stronger Links to both Chronological and MRI Predicted Brain Age Compared to Subcutaneous Adipose Tissue 与皮下脂肪组织相比,内脏脂肪组织与时间和MRI预测的脑年龄有更强的联系
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_106573
Cyrus A. Raji, Somayeh Meysami, Soojin Lee, Saurabh Garg, Nasrin Akbari, Rodrigo Solis Pompa, Ahmed Gouda, Thanh Duc Nguyen, Saqib Basar, Yosef Gavriel Chodakiewitz, David A. Merrill, Amar Patel, Daniel J. Durand, Sam Hashemi

Background

Brain age – an image derived measure from structural brain images on T1 weighted scans may reveal information on Alzheimer's risk. We have previously shown that increased abdominal adipose tissue relates to brain atrophy. We evaluated the links between abdominal adipose tissue and brain age.

Method

A total of 1,164 healthy participants from four sites (mean chronological age 55.17 ± 12.37 years, 52% women; 48% men; 39% non-white) were scanned on 1.5T MR machines with a whole-body protocol. Whole body sequences utilized in the quantitative analyses of abdominal fat were coronal T1 were used to segment visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) segmentation. In this process, a nnU-Net model was used for fully supervised segmentation and ITK-SNAP was used for manual annotation. Brain age was computed using a regression-based 3D Simple Fully Convolutional Network. The model was trained on in-house T1-weighted MRI scans collected from 5,500 healthy individuals, aged 18 to 89 years. Brain age gap (BAG) was computed by subtracting chronological age from brain age. Bivariate correlations between VAT and SAT to chronological and brain age were done with partial correlations adjusted for sex with brain age. VAT and SAT were normalized to total abdominal body fat volume. Chronological age was not adjusted for in brain age models to avoid collinearity.

Result

Mean brain age exceeded chronological age (mean brain age = 56.04 ± 12.65, mean BAG = 0.69) and were highly correlated (r=0.94, p <.001). VAT and SAT were positively related to increased chronological age (VAT: r=0.2780, p = 5.477e-20; r=0.0924, p = 0.002817) and increased brain age (VAT: r=0.2806, p = 2.42e-20; SAT: r=0.0947, p = 0.002189) with VAT being more closely linked to age than SAT. This did not change when adjusting for sex in separate partial correlations between VAT and SAT for brain age (VAT: rp = r=0.2948, p = 2.247e-22; SAT: r=0.1070, p = 0.0005353). No statistically significant link was noted with VAT, SAT, and BAG.

Conclusion

Both VAT and SAT are linked to chronological and brain age with VAT being more strongly linked. VAT may be a key target for modifying brain age and Alzheimer's risk.

脑年龄——从T1加权扫描的脑结构图像中得出的图像可能揭示阿尔茨海默病风险的信息。我们之前已经证明腹部脂肪组织增加与脑萎缩有关。我们评估了腹部脂肪组织和大脑年龄之间的联系。方法在1.5T磁共振成像仪上进行全身扫描,共对来自4个地点的1164名健康受试者(平均年龄55.17±12.37岁,女性52%,男性48%,非白人39%)进行全身扫描。全身序列用于腹部脂肪的定量分析,冠状T1用于分割内脏脂肪组织(VAT)和皮下脂肪组织(SAT)分割。在此过程中,使用nnU‐Net模型进行完全监督分割,使用ITK‐SNAP进行手动标注。脑年龄使用基于回归的3D简单全卷积网络计算。该模型是在收集了5500名年龄在18岁至89岁的健康个体的T1加权MRI扫描数据后进行训练的。脑年龄差距(BAG)由脑年龄减去实足年龄计算得到。VAT和SAT与时间和脑年龄之间的双变量相关性进行了研究,并根据性别和脑年龄调整了部分相关性。VAT和SAT与总腹部体脂量归一化。在脑年龄模型中,没有对实足年龄进行调整,以避免共线性。结果平均脑年龄大于实足年龄(平均脑年龄= 56.04±12.65,平均BAG = 0.69),且高度相关(r=0.94, p < 0.001)。VAT和SAT与增加的实际年龄(VAT: r=0.2780, p = 5.477e‐20;r=0.0924, p = 0.002817)和增加的脑年龄(VAT: r=0.2806, p = 2.42e‐20;SAT: r=0.0947, p = 0.002189)呈正相关,VAT与年龄的关系比SAT更密切。在VAT与SAT与脑年龄的部分相关性中调整性别后,这一点没有改变(VAT: rp = r=0.2948, p = 2.247e‐22;SAT: r=0.1070, p = 0.0005353)。与VAT, SAT和BAG没有统计学上的显著联系。结论VAT和SAT均与实足年龄和脑年龄相关,其中VAT相关性更强。VAT可能是改变大脑年龄和阿尔茨海默病风险的关键目标。
{"title":"Visceral Adipose Tissue Shows Stronger Links to both Chronological and MRI Predicted Brain Age Compared to Subcutaneous Adipose Tissue","authors":"Cyrus A. Raji,&nbsp;Somayeh Meysami,&nbsp;Soojin Lee,&nbsp;Saurabh Garg,&nbsp;Nasrin Akbari,&nbsp;Rodrigo Solis Pompa,&nbsp;Ahmed Gouda,&nbsp;Thanh Duc Nguyen,&nbsp;Saqib Basar,&nbsp;Yosef Gavriel Chodakiewitz,&nbsp;David A. Merrill,&nbsp;Amar Patel,&nbsp;Daniel J. Durand,&nbsp;Sam Hashemi","doi":"10.1002/alz70856_106573","DOIUrl":"10.1002/alz70856_106573","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Brain age – an image derived measure from structural brain images on T1 weighted scans may reveal information on Alzheimer's risk. We have previously shown that increased abdominal adipose tissue relates to brain atrophy. We evaluated the links between abdominal adipose tissue and brain age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A total of 1,164 healthy participants from four sites (mean chronological age 55.17 ± 12.37 years, 52% women; 48% men; 39% non-white) were scanned on 1.5T MR machines with a whole-body protocol. Whole body sequences utilized in the quantitative analyses of abdominal fat were coronal T1 were used to segment visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) segmentation. In this process, a nnU-Net model was used for fully supervised segmentation and ITK-SNAP was used for manual annotation. Brain age was computed using a regression-based 3D Simple Fully Convolutional Network. The model was trained on in-house T1-weighted MRI scans collected from 5,500 healthy individuals, aged 18 to 89 years. Brain age gap (BAG) was computed by subtracting chronological age from brain age. Bivariate correlations between VAT and SAT to chronological and brain age were done with partial correlations adjusted for sex with brain age. VAT and SAT were normalized to total abdominal body fat volume. Chronological age was not adjusted for in brain age models to avoid collinearity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>Mean brain age exceeded chronological age (mean brain age = 56.04 ± 12.65, mean BAG = 0.69) and were highly correlated (r=0.94, <i>p</i> &lt;.001). VAT and SAT were positively related to increased chronological age (VAT: r=0.2780, <i>p</i> = 5.477e-20; r=0.0924, <i>p</i> = 0.002817) and increased brain age (VAT: r=0.2806, <i>p</i> = 2.42e-20; SAT: r=0.0947, <i>p</i> = 0.002189) with VAT being more closely linked to age than SAT. This did not change when adjusting for sex in separate partial correlations between VAT and SAT for brain age (VAT: rp = r=0.2948, <i>p</i> = 2.247e-22; SAT: r=0.1070, <i>p</i> = 0.0005353). No statistically significant link was noted with VAT, SAT, and BAG.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Both VAT and SAT are linked to chronological and brain age with VAT being more strongly linked. VAT may be a key target for modifying brain age and Alzheimer's risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_106573","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medial temporal lobe Tau-Neurodegeneration mismatch from MRI and plasma biomarkers identifies vulnerable and resilient phenotypes with AD 内侧颞叶Tau -神经退行性变与MRI和血浆生物标志物不匹配,可识别AD的易感和弹性表型
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_107051
Xueying Lyu, Nidhi S. Mundada, Christopher A Brown, Niyousha Sadeghpour, Emily McGrew, Michael Tran Duong, Long Xie, Mengjin Dong, Yue Li, Ilya M. Nasrallah, Laura E.M. Wisse, Paul A. Yushkevich, Sandhitsu R. Das, David A. Wolk
<div> <section> <h3> Background</h3> <p>The heterogeneity of Alzheimer's disease (AD) and lack of well-validated markers of non-AD factors (e.g. TDP-43) present a substantial challenge for therapeutics. Our prior work showed discordance between tau (T) and neurodegeneration (N) identified non-AD factors in AD through multi-modality imaging. Here we tried a simplified approach using plasma ptau217 and medial temporal lobe (MTL) morphometry, given this region's common association with co-pathologies, particularly LATE-NC.</p> </section> <section> <h3> Method</h3> <p>We included 349 ADNI participants (188 cognitively normal, 161 MCI/dementia) with paired T1-MRI and plasma ptau217. The MTL was segmented into subregions and further parcellated into 100 bilateral super-points within regional boundaries. T1-MRI-derived thickness and amygdala volume represented N, and plasma <i>p</i>-Tau217 represented T. T-N residuals, calculated through regression across super-points and amygdala, were used for weighted clustering.</p> </section> <section> <h3> Result</h3> <p>P-Tau217 showed strong association with MTL atrophy (Figure 1A). Three distinct data-driven T-N groups were identified based on mismatch patterns (Figure 1B), including a canonical group (N∼T), a vulnerable group (N>T) with negative residuals primarily in anterior hippocampal and extrahippocampal areas, and a resilient group (N<T) with positive residuals.</p> <p>After clustering, group comparisons were restricted to the AD continuum (i.e. A+). While groups differed in regional volumes (e.g., amygdala), tau severity did not vary (Table 1), suggesting these patterns were not driven by AD pathology. The vulnerable group, displayed greater anterior MTL atrophy aligning with their T-N residual patterns, while the resilient group had less atrophy in anterior extrahippocampal area (Figure 2A). Outside the MTL, the vulnerable group showed greater anterior limbic atrophy whereas the resilient group showed less (Figure 2B).</p> <p>The T-N groups differed in Clinical Dementia Rating (CDR) with the vulnerable group having the worst ratings and the resilient group the best (Table 1). Notably, the vulnerable group demonstrated greater baseline memory impairment. Longitudinally, the vulnerable group also declined more severely across multiple cognitive domains while resilient group remained most stable (Figure 2C).</p> </section> <section> <h3> Conclusion</h3> <p>T-N <i>mismatch</i> within MTL using MRI and plasma biomarkers revealed groups with v
阿尔茨海默病(AD)的异质性和缺乏经过充分验证的非AD因素标志物(如TDP - 43)对治疗提出了重大挑战。我们之前的工作显示tau (T)和神经变性(N)之间的不一致,通过多模态成像确定了AD的非AD因素。鉴于该区域与共病理,特别是LATE‐NC的共同关联,我们尝试了一种简化的方法,使用血浆ptau217和内侧颞叶(MTL)形态测定法。方法我们纳入了349名ADNI参与者(188名认知正常,161名MCI/痴呆),配对T1 - MRI和血浆ptau217。MTL被分割成次区域,并在区域边界内进一步细分为100个双边超级点。T1‐MRI衍生的厚度和杏仁核体积代表N,血浆p‐Tau217代表T。通过超点和杏仁核的回归计算得到的T‐N残差用于加权聚类。结果P‐Tau217显示与MTL萎缩密切相关(图1A)。根据不匹配模式确定了三个不同的数据驱动的T - N组(图1B),包括典型组(N ~ T),弱势组(N>;T),残差主要在海马前部和海马外区域为负,弹性组(N<;T)残差为正。聚类后,组间比较仅限于AD连续体(即A+)。虽然各组在区域体积(如杏仁核)上存在差异,但tau的严重程度没有变化(表1),这表明这些模式不是由AD病理驱动的。脆弱组表现出更大的前MTL萎缩,与其T - N残留模式一致,而弹性组海马外区前部萎缩较少(图2A)。在MTL外,脆弱组表现出更大的前边缘萎缩,而弹性组则较少(图2B)。T - N组在临床痴呆评分(CDR)方面存在差异,弱势组评分最差,而弹性组评分最好(表1)。值得注意的是,弱势组表现出更大的基线记忆障碍。纵向上,弱势组在多个认知领域的下降也更严重,而弹性组保持最稳定(图2C)。结论MRI和血浆生物标志物显示MTL中T - N不匹配的群体具有不同的脆弱性/恢复力,弱势群体表现出萎缩和认知模式,提示LATE‐NC。它为个体分层治疗干预提供了一种侵入性小、成本效益高的方法。
{"title":"Medial temporal lobe Tau-Neurodegeneration mismatch from MRI and plasma biomarkers identifies vulnerable and resilient phenotypes with AD","authors":"Xueying Lyu,&nbsp;Nidhi S. Mundada,&nbsp;Christopher A Brown,&nbsp;Niyousha Sadeghpour,&nbsp;Emily McGrew,&nbsp;Michael Tran Duong,&nbsp;Long Xie,&nbsp;Mengjin Dong,&nbsp;Yue Li,&nbsp;Ilya M. Nasrallah,&nbsp;Laura E.M. Wisse,&nbsp;Paul A. Yushkevich,&nbsp;Sandhitsu R. Das,&nbsp;David A. Wolk","doi":"10.1002/alz70856_107051","DOIUrl":"10.1002/alz70856_107051","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The heterogeneity of Alzheimer's disease (AD) and lack of well-validated markers of non-AD factors (e.g. TDP-43) present a substantial challenge for therapeutics. Our prior work showed discordance between tau (T) and neurodegeneration (N) identified non-AD factors in AD through multi-modality imaging. Here we tried a simplified approach using plasma ptau217 and medial temporal lobe (MTL) morphometry, given this region's common association with co-pathologies, particularly LATE-NC.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We included 349 ADNI participants (188 cognitively normal, 161 MCI/dementia) with paired T1-MRI and plasma ptau217. The MTL was segmented into subregions and further parcellated into 100 bilateral super-points within regional boundaries. T1-MRI-derived thickness and amygdala volume represented N, and plasma &lt;i&gt;p&lt;/i&gt;-Tau217 represented T. T-N residuals, calculated through regression across super-points and amygdala, were used for weighted clustering.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Result&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;P-Tau217 showed strong association with MTL atrophy (Figure 1A). Three distinct data-driven T-N groups were identified based on mismatch patterns (Figure 1B), including a canonical group (N∼T), a vulnerable group (N&gt;T) with negative residuals primarily in anterior hippocampal and extrahippocampal areas, and a resilient group (N&lt;T) with positive residuals.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;After clustering, group comparisons were restricted to the AD continuum (i.e. A+). While groups differed in regional volumes (e.g., amygdala), tau severity did not vary (Table 1), suggesting these patterns were not driven by AD pathology. The vulnerable group, displayed greater anterior MTL atrophy aligning with their T-N residual patterns, while the resilient group had less atrophy in anterior extrahippocampal area (Figure 2A). Outside the MTL, the vulnerable group showed greater anterior limbic atrophy whereas the resilient group showed less (Figure 2B).&lt;/p&gt;\u0000 \u0000 &lt;p&gt;The T-N groups differed in Clinical Dementia Rating (CDR) with the vulnerable group having the worst ratings and the resilient group the best (Table 1). Notably, the vulnerable group demonstrated greater baseline memory impairment. Longitudinally, the vulnerable group also declined more severely across multiple cognitive domains while resilient group remained most stable (Figure 2C).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;T-N &lt;i&gt;mismatch&lt;/i&gt; within MTL using MRI and plasma biomarkers revealed groups with v","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_107051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sleep and 24-hour rhythm associations with plasma markers of inflammation in aging 睡眠和24小时节律与衰老过程中炎症的血浆标志物相关
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_105983
Skylar E Weiss
<div> <section> <h3> Background</h3> <p>Disrupted sleep and 24-hour rhythms contribute to age-related inflammation, a key pathway influencing vulnerability to chronic disease and mortality in older adults. Previous studies have explored associations between lifestyle measures and inflammation, but additional research is needed to characterize associations between sleep-wake rhythms and inflammatory cytokines in the context of healthy brain aging.</p> </section> <section> <h3> Method</h3> <p>54 cognitively normal older adults (77.2 ± 6.6 years, 57% female) completed blood draws and 14 days of at-home actigraphy (wrist-worn accelerometry). Plasma samples were analyzed using the Alamar NULISASeq Inflammation panel. Actigraphy analyses focused on nocturnal sleep efficiency, sleep duration, 24-hour relative amplitude, interdaily stability, and intradaily variability. Sixty cytokines and other proteins were selected based on their roles in regulating inflammation. Associations between actigraphy measures and inflammatory markers were tested using linear regression with age, sex, and time between collection (2.0 ± 2.8 years) included as covariates. Multiple comparisons corrections were not used. NULISA <i>p</i>-tau217 was added as a covariate in sensitivity analyses.</p> </section> <section> <h3> Result</h3> <p>Worse sleep and 24-hour rhythms were generally associated with an elevated inflammatory cytokine profile (Figure). Shorter sleep duration was associated with lower levels of IL-1 receptor-like 1 and higher levels of IL-1β. Day-to-day regularity of 24-hour rhythms (interdaily stability) was positively associated with IL-5 receptor subunit A, and within-day fragmentation (intradaily variability) was positively associated with colony stimulating factor 2 receptor beta. Worse sleep efficiency was associated with higher fibroblast growth factor 23. Higher relative amplitude of 24-hour rhythm was associated with lower IL-6. When <i>p</i>-tau217 was added as a covariate, associations remained significant for IL-1β, IL-6, IL-5RA, FGF23, and CSF2RB, but not for IL-1RL1, suggesting that these associations were independent of Alzheimer's disease pathology.</p> </section> <section> <h3> Conclusion</h3> <p>These preliminary findings support the hypothesis that disrupted sleep and 24-hour rhythms are associated with higher pro-inflammatory and lower anti-inflammatory cytokines among healthy older adults. Future work is needed to examine how associations between sleep and inflammation impact cognitive aging trajectories.</p> </section>
背景:睡眠中断和24小时节律有助于年龄相关炎症,这是影响老年人慢性疾病易感性和死亡率的关键途径。先前的研究已经探索了生活方式与炎症之间的关系,但在健康大脑衰老的背景下,还需要进一步的研究来确定睡眠-觉醒节律和炎症细胞因子之间的关系。方法54名认知正常的老年人(77.2±6.6岁,57%为女性)完成了抽血和14天的在家活动记录仪(腕带加速度计)。血浆样本使用Alamar NULISASeq炎症面板进行分析。活动描记分析侧重于夜间睡眠效率、睡眠持续时间、24小时相对振幅、每日间稳定性和每日内变异性。根据它们在调节炎症中的作用,选择了60种细胞因子和其他蛋白质。以年龄、性别和采集时间(2.0±2.8年)为协变量,采用线性回归检验活动测量与炎症标志物之间的相关性。没有使用多重比较校正。在敏感性分析中加入了NULISA p - tau217作为协变量。结果:较差的睡眠和24小时节律通常与炎症细胞因子谱升高相关(图)。较短的睡眠时间与较低水平的IL - 1受体样1和较高水平的IL - 1β相关。24小时节律的日常规律性(每日间的稳定性)与IL - 5受体亚基A呈正相关,而一天内的碎片化(每日变异性)与集落刺激因子2受体β呈正相关。较差的睡眠效率与较高的成纤维细胞生长因子23有关。较高的24小时节律相对振幅与较低的IL - 6相关。当p - tau217作为协变量加入时,IL - 1β、IL - 6、IL - 5RA、FGF23和CSF2RB的相关性仍然显著,但IL - 1RL1的相关性不显著,这表明这些相关性与阿尔茨海默病的病理无关。这些初步发现支持了健康老年人睡眠中断和24小时节律与促炎细胞因子升高和抗炎细胞因子降低相关的假设。未来的工作需要研究睡眠和炎症之间的联系如何影响认知衰老轨迹。
{"title":"Sleep and 24-hour rhythm associations with plasma markers of inflammation in aging","authors":"Skylar E Weiss","doi":"10.1002/alz70856_105983","DOIUrl":"10.1002/alz70856_105983","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Disrupted sleep and 24-hour rhythms contribute to age-related inflammation, a key pathway influencing vulnerability to chronic disease and mortality in older adults. Previous studies have explored associations between lifestyle measures and inflammation, but additional research is needed to characterize associations between sleep-wake rhythms and inflammatory cytokines in the context of healthy brain aging.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;54 cognitively normal older adults (77.2 ± 6.6 years, 57% female) completed blood draws and 14 days of at-home actigraphy (wrist-worn accelerometry). Plasma samples were analyzed using the Alamar NULISASeq Inflammation panel. Actigraphy analyses focused on nocturnal sleep efficiency, sleep duration, 24-hour relative amplitude, interdaily stability, and intradaily variability. Sixty cytokines and other proteins were selected based on their roles in regulating inflammation. Associations between actigraphy measures and inflammatory markers were tested using linear regression with age, sex, and time between collection (2.0 ± 2.8 years) included as covariates. Multiple comparisons corrections were not used. NULISA &lt;i&gt;p&lt;/i&gt;-tau217 was added as a covariate in sensitivity analyses.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Result&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Worse sleep and 24-hour rhythms were generally associated with an elevated inflammatory cytokine profile (Figure). Shorter sleep duration was associated with lower levels of IL-1 receptor-like 1 and higher levels of IL-1β. Day-to-day regularity of 24-hour rhythms (interdaily stability) was positively associated with IL-5 receptor subunit A, and within-day fragmentation (intradaily variability) was positively associated with colony stimulating factor 2 receptor beta. Worse sleep efficiency was associated with higher fibroblast growth factor 23. Higher relative amplitude of 24-hour rhythm was associated with lower IL-6. When &lt;i&gt;p&lt;/i&gt;-tau217 was added as a covariate, associations remained significant for IL-1β, IL-6, IL-5RA, FGF23, and CSF2RB, but not for IL-1RL1, suggesting that these associations were independent of Alzheimer's disease pathology.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;These preliminary findings support the hypothesis that disrupted sleep and 24-hour rhythms are associated with higher pro-inflammatory and lower anti-inflammatory cytokines among healthy older adults. Future work is needed to examine how associations between sleep and inflammation impact cognitive aging trajectories.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 ","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_105983","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Derivation of a structural connectome integrity matrix based on the complex neural circuitry of the aging brain: A multi-modal perspective applied to cognitive aging 基于衰老大脑复杂神经回路的结构连接体完整性矩阵的推导:应用于认知衰老的多模态视角
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_105182
Melissa Lamar, Maude Wagner, Shengwei Zhang, Sue E. Leurgans, Victoria N Poole, Lisa L. Barnes, David A. A. Bennett, David X. Marquez, Julie A Schneider, Konstantinos Arfanakis
<div> <section> <h3> Background</h3> <p>Structural connectome-focused neuroimaging provides an important window into the aging brain; however, few studies address the complexities of mapping structural connectivity in late-life. Of those that do, most either employ ‘lesion-filling’ approaches to calculate connectivity metrics, or statistically adjust for lesions. These reasonable applications of connectome metrics to older adults with brain abnormalities and/or focal lesions may nonetheless obscure the impact of such lesions on (dis-) connectivity and cognitive impairment.</p> </section> <section> <h3> Methods</h3> <p>We applied alternative solutions to 3T neuroimaging data of 1,047 Rush Alzheimer's Disease Center cohort participants [age(years)≈78±7; 61% non-Latino White]. We used an atlas-based definition of the path of white matter connections via a structural connectivity-based atlas, data-driven network edge selection, and multi-modal MRI metrics to reveal subtle distinctions in structural connectome integrity. Global cognition was assessed annually using 19 cognitive measures.</p> </section> <section> <h3> Results</h3> <p>Data-driven network edge selection resulted in 308 major edges contributing to the overall structural connectome integrity matrix (SCIM). Separate principal component analyses (PCAs) of MRI-derived transverse relaxation rates (R<sub>2</sub>), fractional anisotropy, and quantitative susceptibility mapping revealed modality-specific sub-networks. For example, the R<sub>2</sub>-SCIM PCA revealed four sub-networks containing U-fibers within lobes and connections between lobes (Figure 1): Sub-Network 1 was characterized by R<sub>2</sub> integrity within edges involving most frontal nodes (i.e., grey matter regions), all parietal nodes, and key subcortical structures including the basal ganglia; Sub-Network 2 involved most albeit slightly different frontal nodes than Sub-Network 1, nearly all temporal nodes, and key subcortical structures including limbic structures; Sub-Network 3 was primarily characterized by R<sub>2</sub> integrity of edges involving select parietal and temporal nodes and all occipital nodes; Sub-Network 4 involved only the cerebellum, basal ganglia and limbic structures. A linear mixed-effects regression of global cognition containing PCA-derived weighted composite scores representing each R<sub>2</sub>-SCIM sub-network and relevant confounders demonstrated associations of higher R<sub>2</sub> in Sub-Networks 1, 2, and 4 with higher cognition at baseline (<i>p</i>-values≤0.045) and associations of higher R<sub>2</sub> in Sub-Networks 2 and 3 with slower decline in cognition (<i>p</i>-values≤0.02) (Figure 2).</
以结构连接体为中心的神经成像为研究衰老的大脑提供了一个重要的窗口;然而,很少有研究涉及晚年结构连接映射的复杂性。在这些公司中,大多数要么采用“病变填充”方法来计算连通性指标,要么对病变进行统计调整。尽管如此,这些连接组指标在患有脑异常和/或局灶性病变的老年人中的合理应用可能会模糊这些病变对(非)连通性和认知障碍的影响。方法对1047名Rush阿尔茨海默病中心队列参与者的3T神经影像学数据采用替代解决方案[年龄(岁)≈78±7;61%非拉丁裔白人]。我们使用基于图谱的白质连接路径定义,通过基于结构连接的图谱、数据驱动的网络边缘选择和多模态MRI指标来揭示结构连接体完整性的细微差别。全球认知能力每年通过19项认知测量进行评估。结果数据驱动的网络边缘选择产生了308个主要边缘,构成了整体结构连接体完整性矩阵(SCIM)。MRI衍生的横向弛豫率(r2)、分数各向异性和定量敏感性图谱的独立主成分分析(pca)揭示了模态特异性子网络。例如,r2‐SCIM PCA揭示了四个在脑叶和脑叶之间的连接中包含U -纤维的子网络(图1):子网络1的特征是边缘内的r2完整性,涉及大多数额叶节点(即灰质区域)、所有顶叶节点和包括基底神经节在内的关键皮质下结构;子网络2涉及大部分额叶节点,尽管与子网络1略有不同,但几乎所有的颞叶节点,以及包括边缘结构在内的关键皮层下结构;子网络3的主要特征是涉及部分顶叶和颞叶节点以及所有枕叶节点的边缘的r2完整性;亚网络4只涉及小脑、基底神经节和边缘结构。全局认知的线性混合效应回归包含PCA衍生的加权复合分数,代表每个r2‐SCIM子网络和相关混杂因素,结果表明,子网络1、2和4中较高的r2与基线时较高的认知相关(p值≤0.045),子网络2和3中较高的r2与认知下降较慢相关(p值≤0.02)(图2)。我们对老化连接体的理解方法提供了对结构连接体完整性、其潜在子网络及其与认知的关联的全面评估。
{"title":"Derivation of a structural connectome integrity matrix based on the complex neural circuitry of the aging brain: A multi-modal perspective applied to cognitive aging","authors":"Melissa Lamar,&nbsp;Maude Wagner,&nbsp;Shengwei Zhang,&nbsp;Sue E. Leurgans,&nbsp;Victoria N Poole,&nbsp;Lisa L. Barnes,&nbsp;David A. A. Bennett,&nbsp;David X. Marquez,&nbsp;Julie A Schneider,&nbsp;Konstantinos Arfanakis","doi":"10.1002/alz70856_105182","DOIUrl":"10.1002/alz70856_105182","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Structural connectome-focused neuroimaging provides an important window into the aging brain; however, few studies address the complexities of mapping structural connectivity in late-life. Of those that do, most either employ ‘lesion-filling’ approaches to calculate connectivity metrics, or statistically adjust for lesions. These reasonable applications of connectome metrics to older adults with brain abnormalities and/or focal lesions may nonetheless obscure the impact of such lesions on (dis-) connectivity and cognitive impairment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We applied alternative solutions to 3T neuroimaging data of 1,047 Rush Alzheimer's Disease Center cohort participants [age(years)≈78±7; 61% non-Latino White]. We used an atlas-based definition of the path of white matter connections via a structural connectivity-based atlas, data-driven network edge selection, and multi-modal MRI metrics to reveal subtle distinctions in structural connectome integrity. Global cognition was assessed annually using 19 cognitive measures.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Data-driven network edge selection resulted in 308 major edges contributing to the overall structural connectome integrity matrix (SCIM). Separate principal component analyses (PCAs) of MRI-derived transverse relaxation rates (R&lt;sub&gt;2&lt;/sub&gt;), fractional anisotropy, and quantitative susceptibility mapping revealed modality-specific sub-networks. For example, the R&lt;sub&gt;2&lt;/sub&gt;-SCIM PCA revealed four sub-networks containing U-fibers within lobes and connections between lobes (Figure 1): Sub-Network 1 was characterized by R&lt;sub&gt;2&lt;/sub&gt; integrity within edges involving most frontal nodes (i.e., grey matter regions), all parietal nodes, and key subcortical structures including the basal ganglia; Sub-Network 2 involved most albeit slightly different frontal nodes than Sub-Network 1, nearly all temporal nodes, and key subcortical structures including limbic structures; Sub-Network 3 was primarily characterized by R&lt;sub&gt;2&lt;/sub&gt; integrity of edges involving select parietal and temporal nodes and all occipital nodes; Sub-Network 4 involved only the cerebellum, basal ganglia and limbic structures. A linear mixed-effects regression of global cognition containing PCA-derived weighted composite scores representing each R&lt;sub&gt;2&lt;/sub&gt;-SCIM sub-network and relevant confounders demonstrated associations of higher R&lt;sub&gt;2&lt;/sub&gt; in Sub-Networks 1, 2, and 4 with higher cognition at baseline (&lt;i&gt;p&lt;/i&gt;-values≤0.045) and associations of higher R&lt;sub&gt;2&lt;/sub&gt; in Sub-Networks 2 and 3 with slower decline in cognition (&lt;i&gt;p&lt;/i&gt;-values≤0.02) (Figure 2).&lt;/","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_105182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the relationship of perivascular spaces with vascular risk factors, amyloid positivity, and cognitive impairment 评估血管周围间隙与血管危险因素、淀粉样蛋白阳性和认知障碍的关系
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_104241
Swati Rane Levendovszky, Mladen Zecevic, Rebecca J Lepping, Daniel Schwartz, Lisa C Silbert, Sandra A Billinger
<div> <section> <h3> Background</h3> <p>Perivascular space (PVS) burden is an emerging MRI marker of cerebrovascular disease and represents enlarged fluid-filled spaces around blood vessels. It could also indicate stagnated CSF flow that slows amyloid clearance from the brain. Here, we sought to determine which vascular risk factor (BMI, blood pressure, pulse wave velocity) informed PVS burden. We also assessed if PVS burden was associated with amyloid positivity. Finally, we evaluated whether PVS burden was associated with cognitive status.</p> </section> <section> <h3> Method</h3> <p>45 (74±7 years old, 24M) participants from the local ADRC, who underwent MRI and amyloid PET imaging, also participated in a study for pulse wave imaging. Pulse wave ultrasound imaging measures pressure wave propagation through large arteries and is a measure of arterial stiffness. Participants were assigned to two groups: a normal cognition group (<i>N</i> = 15) and a cognitively impaired group with MCI and AD diagnosis (<i>N</i> = 30). PVSs were detected in accordance with Schwartz et al. using T1 and FLAIR images. PVS volumes were normalized by total white matter and defined as PVS burden. Typical Florbetaben PET acquisition, processing, and analyses were performed in AD vulnerable regions with a SUVR1.47 for amyloid positivity. A lasso regression was performed to evaluate which vascular risk factors (pulse wave velocity, systolic and diastolic blood pressure, BMI – found to not be significantly correlated to each other and treated as independent in this study), predicted PVS burden. Since age and sex-dependent differences between the amyloid-positive (<i>N</i> = 17) and amyloid-negative (<i>N</i> = 28) groups were not significant, PVS burden was directly compared with a t-test. Similar comparison was performed between the two cognitive groups.</p> </section> <section> <h3> Result</h3> <p>Figure 1 shows a representative PVS segmentation. Figure 2 shows PET SUVR map with AD vulnerable regions overlaid on top. Lasso regression found no vascular risk factors predictive of PVS burden. PVS burden was significantly higher in amyloid positive (<i>p</i> = 0.05) and cognitively impaired participants (<i>p</i> = 0.02, Figure 3).</p> </section> <section> <h3> Conclusion</h3> <p>PVS burden was significantly greater in amyloid-positive individuals compared to amyloid-negative individuals, likely due to the impaired CSF flow in the PVSs associated with glymphatic clearance. Our moderate sample size could explain the absence of associations with vascular risk factors.</p>
血管周围空间(PVS)负担是脑血管疾病的一个新兴MRI标记,它代表血管周围充满液体的空间增大。这也可能表明脑脊液流动停滞,减缓了大脑中淀粉样蛋白的清除。在这里,我们试图确定哪些血管危险因素(BMI、血压、脉搏波速度)影响PVS负担。我们还评估了PVS负担是否与淀粉样蛋白阳性相关。最后,我们评估了PVS负担是否与认知状态有关。方法45例(74±7岁,24M)局部ADRC患者行MRI和淀粉样PET成像,同时进行脉搏波成像研究。脉冲波超声成像测量压力波在大动脉中的传播,是动脉硬度的一种测量方法。参与者被分为两组:认知正常组(N = 15)和认知受损组(N = 30), MCI和AD诊断。根据Schwartz等人使用T1和FLAIR图像检测PVSs。PVS体积按总白质归一化并定义为PVS负荷。典型的Florbetaben PET采集、处理和分析在AD易感区域进行,淀粉样蛋白阳性SUVR1.47。采用套索回归来评估哪些血管危险因素(脉搏波速度、收缩压和舒张压、BMI -发现彼此之间没有显著相关性,在本研究中被视为独立)预测PVS负担。由于淀粉样蛋白阳性(N = 17)和淀粉样蛋白阴性(N = 28)组之间的年龄和性别依赖性差异不显著,因此PVS负担直接采用t检验进行比较。在两个认知组之间进行了类似的比较。图1显示了一个具有代表性的pv分割。图2显示了PET SUVR地图,上面覆盖了AD脆弱区域。Lasso回归未发现预测PVS负担的血管危险因素。淀粉样蛋白阳性(p = 0.05)和认知障碍参与者的PVS负担显著增加(p = 0.02,图3)。结论淀粉样蛋白阳性个体的PVS负荷明显大于淀粉样蛋白阴性个体,这可能是由于与淋巴清除相关的PVS中脑脊液流量受损。我们适度的样本量可以解释与血管危险因素的相关性缺失。
{"title":"Evaluating the relationship of perivascular spaces with vascular risk factors, amyloid positivity, and cognitive impairment","authors":"Swati Rane Levendovszky,&nbsp;Mladen Zecevic,&nbsp;Rebecca J Lepping,&nbsp;Daniel Schwartz,&nbsp;Lisa C Silbert,&nbsp;Sandra A Billinger","doi":"10.1002/alz70856_104241","DOIUrl":"10.1002/alz70856_104241","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Perivascular space (PVS) burden is an emerging MRI marker of cerebrovascular disease and represents enlarged fluid-filled spaces around blood vessels. It could also indicate stagnated CSF flow that slows amyloid clearance from the brain. Here, we sought to determine which vascular risk factor (BMI, blood pressure, pulse wave velocity) informed PVS burden. We also assessed if PVS burden was associated with amyloid positivity. Finally, we evaluated whether PVS burden was associated with cognitive status.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;45 (74±7 years old, 24M) participants from the local ADRC, who underwent MRI and amyloid PET imaging, also participated in a study for pulse wave imaging. Pulse wave ultrasound imaging measures pressure wave propagation through large arteries and is a measure of arterial stiffness. Participants were assigned to two groups: a normal cognition group (&lt;i&gt;N&lt;/i&gt; = 15) and a cognitively impaired group with MCI and AD diagnosis (&lt;i&gt;N&lt;/i&gt; = 30). PVSs were detected in accordance with Schwartz et al. using T1 and FLAIR images. PVS volumes were normalized by total white matter and defined as PVS burden. Typical Florbetaben PET acquisition, processing, and analyses were performed in AD vulnerable regions with a SUVR1.47 for amyloid positivity. A lasso regression was performed to evaluate which vascular risk factors (pulse wave velocity, systolic and diastolic blood pressure, BMI – found to not be significantly correlated to each other and treated as independent in this study), predicted PVS burden. Since age and sex-dependent differences between the amyloid-positive (&lt;i&gt;N&lt;/i&gt; = 17) and amyloid-negative (&lt;i&gt;N&lt;/i&gt; = 28) groups were not significant, PVS burden was directly compared with a t-test. Similar comparison was performed between the two cognitive groups.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Result&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Figure 1 shows a representative PVS segmentation. Figure 2 shows PET SUVR map with AD vulnerable regions overlaid on top. Lasso regression found no vascular risk factors predictive of PVS burden. PVS burden was significantly higher in amyloid positive (&lt;i&gt;p&lt;/i&gt; = 0.05) and cognitively impaired participants (&lt;i&gt;p&lt;/i&gt; = 0.02, Figure 3).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;PVS burden was significantly greater in amyloid-positive individuals compared to amyloid-negative individuals, likely due to the impaired CSF flow in the PVSs associated with glymphatic clearance. Our moderate sample size could explain the absence of associations with vascular risk factors.&lt;/p&gt;\u0000 ","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_104241","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social determinants of pharmacological dementia management: results from IDEAS 痴呆药理学管理的社会决定因素:IDEAS的结果
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_107370
Margo B. Heston, Charles C. Windon, Lucy Hanna, Constantine Gatsonis, Maria C. Carrillo, Charles Apgar, Peggye Dilworth-Anderson, Bruce E Hillner, Andrew March, Barry A Siegel, Rachel A. Whitmer, Consuelo H. Wilkins, Renaud La Joie, Gil D. Rabinovici
<div> <section> <h3> Background</h3> <p>Socioeconomic vulnerabilities and healthcare environment contribute to disparities in dementia assessment. Whether these affect dementia management, however, remains unclear. We used Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) study data to compare the impact of amyloid PET on pharmacological management across social factors, patient comorbidities, and physician practice settings.</p> </section> <section> <h3> Methods</h3> <p>We analyzed rates of pharmacological change in IDEAS participants with visually interpretable amyloid PET, completed pre- and post-PET case reports, social determinants (racioethnic identity of Asian, Black, Hispanic, or White, area deprivation index (ADI), living arrangement, education) and medical history. Outcomes included any change between pre-PET and post-PET visits in prescription of Alzheimer's disease (AD) drugs, and of non-AD drugs treating dementia risk factors or affecting cognition/mood/behavior. We used multilevel logistic regression with a random site intercept to test whether the probability of change in management associated with social determinants, race/ADI interactions with amyloid-positivity, comorbidities, and clinical setting, adjusting for demographics.</p> </section> <section> <h3> Results</h3> <p>Among 10,904 cognitively impaired participants (Table 1), 90% were White, with 4.8% Hispanic, 3.1% Black, and 1.8% Asian representation. 10% resided in highly disadvantaged neighborhoods (ADI 9-10), 83% lived with ≥1 person, and 68% were educated past high school.</p> <p>Pre-FDR correction (adjusted <i>P</i>-values: Table 1), AD drug management change was associated with dyslipidemia (OR [95% CI]=0.88 [0.80-0.97], <i>P</i><sub>unadj</sub>=.007), depression (0.87 [0.77, 0.97], <i>P</i><sub>unadj</sub>=.014), and tobacco use (0.87 [0.77, 0.99], <i>P</i><sub>unadj</sub>=.028). Non-AD drug management change was associated with depression (1.73 [1.51, 1.97], <i>P</i><sub>unadj</sub><.001), group practice (0.72 [0.56, 0.93], <i>P</i><sub>unadj</sub>=.012) and ADI in amyloid-positive participants (0.68 [0.47, 0.98], <i>P</i><sub>unadj</sub>=.04). Change rates were also associated with amyloid-PET status, impairment level, and etiology. Figure 1 summarizes change rates across social factors.</p> </section> <section> <h3> Conclusions</h3> <p>These results suggest amyloid status, cognitive impairment level, dementia etiology, and comorbidities may inform pharmacological decision-making. Clarifying dementia etiology with amyloid PET m
背景:社会经济脆弱性和医疗环境导致痴呆评估的差异。然而,这些因素是否会影响痴呆症的管理尚不清楚。我们使用痴呆成像-淀粉样蛋白扫描证据(IDEAS)研究数据来比较淀粉样蛋白PET对社会因素、患者合并症和医生实践环境的药理学管理的影响。方法:我们用视觉可解释的淀粉样蛋白PET分析IDEAS参与者的药理学变化率,完成PET前后的病例报告,社会决定因素(亚洲人、黑人、西班牙人或白人的种族身份、区域剥夺指数(ADI)、生活安排、教育程度)和病史。结果包括PET前和PET后访问阿尔茨海默病(AD)药物处方的任何变化,以及治疗痴呆危险因素或影响认知/情绪/行为的非AD药物。我们使用随机站点截距的多水平逻辑回归来检验管理变化的概率是否与社会决定因素、种族/ADI与淀粉样蛋白阳性的相互作用、合并症和临床环境相关,并根据人口统计学进行调整。结果在10,904名认知障碍参与者中(表1),90%为白人,4.8%为西班牙裔,3.1%为黑人,1.8%为亚洲人。10%的人居住在高度弱势社区(ADI 9‐10),83%的人与≥1人住在一起,68%的人受过高中以上教育。FDR校正前(调整P值:表1),AD药物管理改变与血脂异常(OR [95% CI]=0.88[0.80‐0.97],P unadj = 0.007)、抑郁(0.87 [0.77,0.97],P unadj = 0.014)和吸烟(0.87 [0.77,0.99],P unadj = 0.028)相关。非AD药物管理改变与淀粉样蛋白阳性参与者的抑郁(1.73 [1.51,1.97],P unadj =. 001)、群体实践(0.72 [0.56,0.93],P unadj =.012)和ADI (0.68 [0.47, 0.98], P unadj =.04)相关。变化率还与淀粉样蛋白- PET状态、损伤水平和病因有关。图1总结了不同社会因素的变化率。结论:这些结果表明淀粉样蛋白状态、认知障碍水平、痴呆病因和合并症可能为药理学决策提供信息。例如,用淀粉样蛋白PET澄清痴呆的病因可能有助于临床医生优化治疗计划,以解决认知障碍老年人管理不善的抑郁症。此外,社会经济劣势可能限制淀粉样蛋白阳性的临床反应。在New IDEAS中的复制和对医疗保险索赔的检查将有助于阐明PET前管理和管理变化的差异是否主要是由评估和医疗保健的准入障碍驱动的。
{"title":"Social determinants of pharmacological dementia management: results from IDEAS","authors":"Margo B. Heston,&nbsp;Charles C. Windon,&nbsp;Lucy Hanna,&nbsp;Constantine Gatsonis,&nbsp;Maria C. Carrillo,&nbsp;Charles Apgar,&nbsp;Peggye Dilworth-Anderson,&nbsp;Bruce E Hillner,&nbsp;Andrew March,&nbsp;Barry A Siegel,&nbsp;Rachel A. Whitmer,&nbsp;Consuelo H. Wilkins,&nbsp;Renaud La Joie,&nbsp;Gil D. Rabinovici","doi":"10.1002/alz70856_107370","DOIUrl":"10.1002/alz70856_107370","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Socioeconomic vulnerabilities and healthcare environment contribute to disparities in dementia assessment. Whether these affect dementia management, however, remains unclear. We used Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) study data to compare the impact of amyloid PET on pharmacological management across social factors, patient comorbidities, and physician practice settings.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We analyzed rates of pharmacological change in IDEAS participants with visually interpretable amyloid PET, completed pre- and post-PET case reports, social determinants (racioethnic identity of Asian, Black, Hispanic, or White, area deprivation index (ADI), living arrangement, education) and medical history. Outcomes included any change between pre-PET and post-PET visits in prescription of Alzheimer's disease (AD) drugs, and of non-AD drugs treating dementia risk factors or affecting cognition/mood/behavior. We used multilevel logistic regression with a random site intercept to test whether the probability of change in management associated with social determinants, race/ADI interactions with amyloid-positivity, comorbidities, and clinical setting, adjusting for demographics.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Among 10,904 cognitively impaired participants (Table 1), 90% were White, with 4.8% Hispanic, 3.1% Black, and 1.8% Asian representation. 10% resided in highly disadvantaged neighborhoods (ADI 9-10), 83% lived with ≥1 person, and 68% were educated past high school.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;Pre-FDR correction (adjusted &lt;i&gt;P&lt;/i&gt;-values: Table 1), AD drug management change was associated with dyslipidemia (OR [95% CI]=0.88 [0.80-0.97], &lt;i&gt;P&lt;/i&gt;&lt;sub&gt;unadj&lt;/sub&gt;=.007), depression (0.87 [0.77, 0.97], &lt;i&gt;P&lt;/i&gt;&lt;sub&gt;unadj&lt;/sub&gt;=.014), and tobacco use (0.87 [0.77, 0.99], &lt;i&gt;P&lt;/i&gt;&lt;sub&gt;unadj&lt;/sub&gt;=.028). Non-AD drug management change was associated with depression (1.73 [1.51, 1.97], &lt;i&gt;P&lt;/i&gt;&lt;sub&gt;unadj&lt;/sub&gt;&lt;.001), group practice (0.72 [0.56, 0.93], &lt;i&gt;P&lt;/i&gt;&lt;sub&gt;unadj&lt;/sub&gt;=.012) and ADI in amyloid-positive participants (0.68 [0.47, 0.98], &lt;i&gt;P&lt;/i&gt;&lt;sub&gt;unadj&lt;/sub&gt;=.04). Change rates were also associated with amyloid-PET status, impairment level, and etiology. Figure 1 summarizes change rates across social factors.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;These results suggest amyloid status, cognitive impairment level, dementia etiology, and comorbidities may inform pharmacological decision-making. Clarifying dementia etiology with amyloid PET m","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_107370","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced AI Techniques for Dementia Prediction using MRI Imaging 利用核磁共振成像预测痴呆症的先进人工智能技术
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-01-10 DOI: 10.1002/alz70856_107381
Saira Kiran, Jingchun Chen

Background

Dementia is a broad category of cognitive decline that affects a person's ability to perform everyday tasks. Unfortunately, there is no cure for dementia, and diagnosis usually happens at later stages when symptoms have significantly progressed. Early detection and accurate staging of dementia could slow down symptom progression and improve the quality of life for affected individuals. In recent years, deep Learning algorithms have emerged as a powerful tool in the early dementia diagnosis. By utilizing MRI images, deep learning techniques can effectively classify dementia at different stages, enabling quicker and more targeted interventions.

Method

We used an MRI dataset from Kaggle, categorized into four classes: non-dementia, very mild dementia, mild dementia, and moderate dementia. The dataset was highly imbalanced, with only 1% of images representing moderate dementia. To address this, we trained a 6-layered Convolutional Neural Network (CNN) using two approaches: (1) a standard 6-layer CNN model and (2) a CNN with SMOTE (Synthetic Minority Over-sampling Technique) to mitigate class imbalance. Model performance was evaluated using accuracy, precision, recall, F1 score, confusion matrix, as well as accuracy and loss curves.

Result

Our SMOTE-CNN model, incorporated the SMOTE technique, showed significant improvements in classifying the four categories of dementia compared to the standard CNN model. The SMOTE-CNN model achieved an overall accuracy of 99%, while the standard CNN model had an accuracy of 71%. Precision, recall, and F1-scores for the SMOTE-CNN model were also notably higher, with perfect scores (1.00) for the 'Mild-Demented' and 'Moderate-Demented' classes, and near-perfect scores (0.99) for the 'Non-Demented' and 'Very Mild-Demented' classes. These results highlight the effectiveness of SMOTE in addressing class imbalance and improving model performance for dementia stage classification.

Conclusion

The results highlight deep learning's potential in enhancing dementia prediction and early detection, leading to better disease staging and management. By addressing class imbalance, we significantly boosted model performance. Future work should focus on validating with independent datasets and incorporating more balanced data to improve generalizability. Additionally, applying the CNN model to real-world data could further enhance dementia prediction and public health outcomes.

痴呆症是一种广泛的认知能力下降,影响一个人执行日常任务的能力。不幸的是,痴呆症无法治愈,通常在症状明显恶化的晚期才会被诊断出来。早期发现和准确的痴呆分期可以减缓症状的进展,改善患者的生活质量。近年来,深度学习算法已成为早期痴呆症诊断的有力工具。通过利用MRI图像,深度学习技术可以有效地对不同阶段的痴呆症进行分类,从而实现更快、更有针对性的干预。方法:我们使用来自Kaggle的MRI数据集,将其分为四类:非痴呆、极轻度痴呆、轻度痴呆和中度痴呆。数据集高度不平衡,只有1%的图像代表中度痴呆。为了解决这个问题,我们使用两种方法训练了一个6层卷积神经网络(CNN):(1)一个标准的6层CNN模型;(2)一个带有SMOTE(合成少数派过采样技术)的CNN来减轻类不平衡。使用准确率、精密度、召回率、F1分数、混淆矩阵以及准确率和损失曲线来评估模型的性能。与标准CNN模型相比,我们的SMOTE - CNN模型结合了SMOTE技术,在对四类痴呆进行分类方面显示出显著的改进。SMOTE - CNN模型的总体准确率为99%,而标准CNN模型的准确率为71%。SMOTE - CNN模型的精度、召回率和F1得分也明显更高,“轻度-痴呆”和“中度-痴呆”类别的得分为满分(1.00),“非痴呆”和“非常轻度-痴呆”类别的得分为接近满分(0.99)。这些结果突出了SMOTE在解决类别不平衡和提高痴呆阶段分类模型性能方面的有效性。结论深度学习在增强痴呆预测和早期发现、改善疾病分期和管理方面具有潜力。通过解决类的不平衡,我们显著提高了模型的性能。未来的工作应侧重于使用独立的数据集进行验证,并结合更平衡的数据来提高概括性。此外,将CNN模型应用于现实世界的数据可以进一步提高痴呆症的预测和公共卫生结果。
{"title":"Advanced AI Techniques for Dementia Prediction using MRI Imaging","authors":"Saira Kiran,&nbsp;Jingchun Chen","doi":"10.1002/alz70856_107381","DOIUrl":"10.1002/alz70856_107381","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dementia is a broad category of cognitive decline that affects a person's ability to perform everyday tasks. Unfortunately, there is no cure for dementia, and diagnosis usually happens at later stages when symptoms have significantly progressed. Early detection and accurate staging of dementia could slow down symptom progression and improve the quality of life for affected individuals. In recent years, deep Learning algorithms have emerged as a powerful tool in the early dementia diagnosis. By utilizing MRI images, deep learning techniques can effectively classify dementia at different stages, enabling quicker and more targeted interventions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>We used an MRI dataset from Kaggle, categorized into four classes: non-dementia, very mild dementia, mild dementia, and moderate dementia. The dataset was highly imbalanced, with only 1% of images representing moderate dementia. To address this, we trained a 6-layered Convolutional Neural Network (CNN) using two approaches: (1) a standard 6-layer CNN model and (2) a CNN with SMOTE (Synthetic Minority Over-sampling Technique) to mitigate class imbalance. Model performance was evaluated using accuracy, precision, recall, F1 score, confusion matrix, as well as accuracy and loss curves.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>Our SMOTE-CNN model, incorporated the SMOTE technique, showed significant improvements in classifying the four categories of dementia compared to the standard CNN model. The SMOTE-CNN model achieved an overall accuracy of 99%, while the standard CNN model had an accuracy of 71%. Precision, recall, and F1-scores for the SMOTE-CNN model were also notably higher, with perfect scores (1.00) for the 'Mild-Demented' and 'Moderate-Demented' classes, and near-perfect scores (0.99) for the 'Non-Demented' and 'Very Mild-Demented' classes. These results highlight the effectiveness of SMOTE in addressing class imbalance and improving model performance for dementia stage classification.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The results highlight deep learning's potential in enhancing dementia prediction and early detection, leading to better disease staging and management. By addressing class imbalance, we significantly boosted model performance. Future work should focus on validating with independent datasets and incorporating more balanced data to improve generalizability. Additionally, applying the CNN model to real-world data could further enhance dementia prediction and public health outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 S2","pages":""},"PeriodicalIF":11.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz70856_107381","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Alzheimer's & Dementia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1